Abstract
Prostate cancer is largely a disease of older men, with more than 90% of mortality observed in patients over 65 years. In the metastatic setting, a number of treatment options are available, with androgen-deprivation therapy being the first-choice, but few studies have examined the feasibility and efficacy of endocrine therapy and chemotherapy in men aged 70 years or older. Since the preservation of quality of life is the main objective of treatment in metastatic prostate cancer, every therapeutic decision should be conditioned by results of a geriatric comprehensive assessment.
Keywords::
Acknowledgements
The authors thank Catia Bassi for help in the preparation of the manuscript.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.